asymmetrical dimethylarginine

asymmetrical dimethylarginine

(dī″meth″ĭl-ar′jĭ-nēn″)
An endogenous inhibitor of nitric acid synthase, an enzyme found in endothelial cells. Its concentration is elevated in patients with chronic kidney disease. It has been proposed as a biomarker of and risk factor for cardiovascular disease.
References in periodicals archive ?
They also measured increases in plasma nitric oxide levels and decreases in asymmetrical dimethylarginine, thiobarbituric acid reactive substance, soluble Fas ligand, soluble CD40 ligand, tumor necrosis factor-alpha, interleukin (IL)-6 and IL-8.
In the past 15 years, scientists mainly focused on asymmetrical dimethylarginine (ADMA), the most potent endogenous nitric oxide (NO) synthase inhibitor.
Determination of asymmetrical dimethylarginine by capillary electrophoresis-laser-induced fluorescence.
In that clinical study, effects of nebivolol and metoprolol on serum asymmetrical dimethylarginine (ADMA) levels, an indicator of endothelial dysfunction, were compared.
The insufficiency of substrate like the decrease in L-arginine in endothelial cells or any defect in the transport of L-arginine into the cell, the existence of NOS inhibitors like asymmetrical dimethylarginine (ADMA) and NG-monomethyl-L-arginine (L-NMMA), increase in the reactive oxygen molecules, the decrease in the diffusion of NO due to intimal thickening, the mutations in the eNOS gene expression, increase in the catabolism of NO, cofactor insufficiency and increase in the vasoconstrictor molecules released from endothelium are the other mechanism that must be considered in endothelial dysfunction.
Asymmetrical dimethylarginine (ADMA) [6] an endogenous inhibitor of endothelial nitric oxide synthase, is increased in conditions associated with increased risk of atherosclerosis, such as impaired renal function (1-4), hypercholesterolemia (5), hypertriglyceridemia (6), insulin resistance (7), diabetes mellitus (8), hyperhomocysteinemia (9), and hypertension (10).
Erectile dysfunction in patients with cardiovascular disease and diabetes: evidence for disturbed relation of L-arginine and the endogenous inhibitor of NO-synthase asymmetrical dimethylarginine (ADMA).
Full browser ?